Joseph F. Clark, Ph.D.

Today’s article is co-authored by Dr. J.F. Clark, Professor of Neurology and Dr. O. Choutka, Chief Neurosurgery Resident, University of Cincinnati.

As a person who has been trying to “help” people for an entire career. Being on the cusp of producing a drug that will drastically improve the lives of numerous patients is humbling and daunting.

If you have a family member or patient with one of the creatine deficiency syndromes, especially the creatine transporter deficiency, please join our facebook group (https://www.facebook.com/?ref=home#!/home.php?sk=group_127389967322193&ap=1) where we will keep people apprised of our latest research and development.

Some of the most experienced researchers concerning creatine and creatine deficiencies are in Cincinnati working hard to treat these patients

I’m currently working on a fairly large grant application for a company. The company wants me to do research on a subject on which I am very comfortable and knowledgeable. The process of writing and securing a research agreement with a company is much different than with the NIH, NSF or most charitable foundations. I [...]

Let me say up front, this may be the most contentious blog I’ve written. So, beware. The definition of an orphan drug is that the market for said drug is less than 200,000 patients. This number of patients is considered to be not sufficient to be financially successful for drug companies to develop drugs. Orphan [...]